Recently, a study indicated that elevated serum soluble TGFβ levels at diagnosis predict poor progression-free survival (PFS) and overall survival (OS) in unresectable pancreatic cancer compared to patients with a low level of soluble TGFβ (OS 13.7 vs. 9.2 months; HR 2.602; p = 0.004; PFS 9.0 vs. 5.8 months; HR 2.010; p = 0.034) [35]. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.